5 mg vial
LL-37 5 mg vial: how to reconstitute it
What a 5 mg vial of LL-37 becomes once it is mixed, and what each dose reported in the sources draws to on a syringe. Every figure is arithmetic on the vial size in the heading — none of it is a recommendation, and the doses are the ones our sources describe rather than ones we picked.
Leading with
5 mg + 5 mL bacteriostatic water = 1 mg/mL
Chosen because it puts the reported doses on readable marks of a 1 mL U-100 syringe. Other volumes are perfectly valid — the dilution table further down covers them, and the concentration changes what every dose draws to.
What each reported dose draws to
At 1 mg/mL, on a 1 mL U-100 syringe. Every row names the source it came from, and a trial protocol and a community convention are not the same kind of information.
| Goal | Dose | Units | Doses in this vial | Source |
|---|---|---|---|---|
| Topical application, as studiedApplied to the wound twice weekly in the trial protocol · Topical | 500 mcg – 3.2 mg | from 50 unitstop of the range needs a second vial | 10 | Clinical trial |
| Commonly described community protocol, injectedDaily, in short courses · Subcutaneous | 100 mcg – 500 mcg | 10 units – 50 units | 50 | Community practice |
Check every figure against the vial in front of you before drawing. Vials are filled with an overage and labels are not a guarantee. Change any of these numbers in the calculator.
Week by week
Published schedules only. Most compounds on this site have no week-by-week schedule from any source, and where that is the case this section does not appear rather than being filled in.
Reported community progression
Community practice| Week | Dose | Units | Frequency |
|---|---|---|---|
| 1 | 50 mcg | 5 units | Once daily |
| 2 | 100 mcg | 10 units | Once daily |
| 3 | 150 mcg | 15 units | Once daily |
| 4 | 200 mcg | 20 units | Once daily |
| 5 | 250 mcg | 25 units | Once daily |
| 6 | 300 mcg | 30 units | Once daily |
| 7 | 350 mcg | 35 units | Once daily |
| 8 | 400 mcg | 40 units | Once daily |
A progression described in community sources, not a finding. No dose-ranging study establishes these steps, and the compilation they come from contained arithmetic errors in its own syringe figures — so the doses are reproduced and none of its unit conversions are.
What the whole schedule costs
Vials of this size needed to work through each step, at 5 mL per vial. The dose changes as you go, so this is not one number times a number of weeks — it is each step costed separately and added up.
Reported community progression
| Week | Dose | Doses | 5 mg vials |
|---|---|---|---|
| 1 | 50 mcg | 7 | 1 |
| 2 | 100 mcg | 7 | 1 |
| 3 | 150 mcg | 7 | 1 |
| 4 | 200 mcg | 7 | 1 |
| 5 | 250 mcg | 7 | 1 |
| 6 | 300 mcg | 7 | 1 |
| 7 | 350 mcg | 7 | 1 |
| 8 | 400 mcg | 7 | 1 |
Reaching the end of the defined steps takes 8 vials of 5 mg over 8 weeks.
Steps whose dose exceeds this vial are marked rather than counted — at that point a larger vial is the answer, not more small ones. Nothing here accounts for a dropped vial, a held step or a dose your prescriber changes, all of which happen.
If you add a different amount of water
The same 5 mg of compound, at four common volumes. More water means a larger, easier-to-measure draw of a weaker solution; less water means the opposite. The amount of compound you inject is identical in every row — only the volume carrying it changes.
| Water added | Concentration | 500 mcg draws to |
|---|---|---|
| 1 mL | 5 mg/mL | 10 units units · 0.1 mL |
| 2 mL | 2.5 mg/mL | 20 units units · 0.2 mL |
| 3 mL | 1.667 mg/mL | 30 units units · 0.3 mL |
| 5 mLshown above | 1 mg/mL | 50 units units · 0.5 mL |
Storage
Before mixing
Refrigerated at 2–8 °C, protected from light.
After mixing
Refrigerated at 2–8 °C. Do not freeze once mixed. LL-37 adsorbs to plastic, so a substantial fraction can be lost to the walls of the container. Glass is preferable.
Other vial sizes
The same compound, different arithmetic.
Arithmetic on the vial size named above and the doses our sources report. Nothing here is a recommendation, a protocol or medical advice, and no clinician has reviewed it. Some rows describe community practice, which is not evidence that a dose is safe or effective. Speak to a licensed healthcare provider before acting on any of it.
Sources for the doses above are listed in full on the LL-37 profile, each with the trial or label it came from.